4.5 Article

Bevacizumab (Avastin)

Journal

AMERICAN JOURNAL OF NEURORADIOLOGY
Volume 31, Issue 2, Pages 235-236

Publisher

AMER SOC NEURORADIOLOGY
DOI: 10.3174/ajnr.A1987

Keywords

-

Ask authors/readers for more resources

Bevacizumab is a humanized monoclonal antibody that was the first FDA approved therapy designed to inhibit angiogenesis. This paper will review the mechanism of action and clinical role of this antiangiogenic agent.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available